Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
- Conditions
- Neoplasms
- Interventions
- Biological: RobatumumabBiological: TrastuzumabDrug: CarboplatinDrug: EpirubicinDrug: EverolimusDrug: GemcitabineBiological: CetuximabDrug: 5-FUDrug: ErlotinibDrug: PaclitaxelDrug: CisplatinDrug: IrinotecanDrug: Folinic Acid
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00954512
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Biological: bevacizumabDrug: FOLFIRI regimenDrug: fluorouracilDrug: irinotecan hydrochlorideDrug: leucovorin calcium
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 492
- Registration Number
- NCT00952029
- Locations
- 🇫🇷
Centre Bourgogne, Lille, France
🇫🇷Croix Rousse, Lyon, France
🇫🇷CHU La Timone, Marseille, France
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
- Conditions
- Gastric Cancer
- Interventions
- Drug: OxaliplatinDrug: IrinotecanDrug: 5-FluorouracilDrug: LeucovorinProcedure: Gastrectomy and/or metastasectomy
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00941655
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT00940303
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 28
- Registration Number
- NCT00940316
- Locations
- 🇺🇸
Hematology/Oncology Associates, Chicago, Illinois, United States
🇺🇸Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
🇺🇸Hope Cancer Center, Terre Haute, Indiana, United States
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
- Conditions
- Metastatic CancerColorectal Cancer
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Registration Number
- NCT00936832
- Locations
- 🇫🇷
Hopital Ambroise Pare, Boulogne Billancourt, France
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
- Conditions
- Colorectal Cancer
- Interventions
- Biological: Dalotuzumab 10 mg/kgBiological: CetuximabDrug: IrinotecanBiological: Dalotuzumab 15/7.5 mg/kg
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00925015
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
- Conditions
- Esophageal CancerStomach CancerGastric Cancer
- Interventions
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 88
- Registration Number
- NCT00911820
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT00891930
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
- Conditions
- Newly Diagnosed High-Grade GliomasDiffuse Intrinsic Pontine Glioma
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 27
- Registration Number
- NCT00890786
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.